Type 1 Diabetes

Catch up with major trial results, key FDA approvals, and more.

MannKind Therapeutics has announced new starting dose recommendations for patients with type 1 diabetes switching from injected or insulin pump mealtime therapy.

An audio recap of the top 5 stories in healthcare news from the week of 01/04-01/10.

An audio recap of the top 5 stories in healthcare news from the week of 01/04-01/10.

According to an announcement by parent company Medtronic, the MiniMed Go app is expected to launch in the spring of 2026.

The Q4 recap for endocrinology spotlights major FDA decisions, updates to diabetes care standards, and key clinical trial updates.

Data from the ongoing phase 4 PETITE-T1D study, highlighting the substantially reduced progression to stage 3 T1D, headline the application.

An audio recap of the top 5 stories in healthcare news from the week of 12/28-1/3.

In a new study, children exposed to gestational diabetes showed lower FEV1 and increased odds of current asthma at ages 8–9 years.

Catch up with major trial results, key clinician insights, and more.

Results from the INTIMET study have shown no significant differences between metformin and placebo in liver, muscle, or adipose tissue insulin resistance.

McGill emphasizes new exciting data shared at ACR 2025.

Finerenone significantly reduces UACR in type 1 diabetes patients with chronic kidney disease, offering new hope for treatment.

Stay up to date with the groundbreaking FDA decisions, critical trial updates, and more news from the last month.

Alterations in appetite and weight may have influenced abdominal adiposity, as well as inflammatory and cardiometabolic markers.

FDA launches the Commissioner’s National Priority Voucher program, expediting drug reviews for critical health needs.

A total of 8 acute and chronic disease factors, including hypertension, obesity, and physical inactivity, compound to increase mortality and CVD risk.

An audio recap of the top 5 stories in healthcare news from the week of 10/12-18.

Nijhoff discusses the positive results of the first portion of the phase 1/2/3 trial and its implications for the underserved T1D patient population.

This episode covers the upcoming glucose monitor Biolinq Shine, the Insulin Icodec FDA resubmission, and the end of Eli Lilly's work in T2D.

Celebrate 150 episodes of Diabetes Dialogue as hosts reflect on advancements in diabetes technology and impactful discussions in patient care.

The sBLA for insulin human Inhalation Powder in children and adolescents with type 1 or type 2 diabetes was assigned a PDUFA target action date of May 29, 2026.

A recent study indicates the potential benefits of consistent follow-up in diabetes through tele-education, teleconsultation, and digital data support.

Investigators urge clinicians to support teenage patients with type 1 diabetes in managing their blood sugar and transitioning to adult care.

The Q3 recap for endocrinology spotlights major FDA decisions, new guidelines for managing diabetes during pregnancy, and major clinical trial updates.